A04.7
Conditions
Interventions
Group 1: In dependence on the patients request, two stool-administration routes are offered:
1) Application via a nasoduodenale probe or 2) application via the endoscope during the Koloscopy (in th
Sponsors
Universitätsklinik für Gastroenterologie, Hepatologie und Infektiologie
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Patient information and consent 2. age> 18 years 3. Life expectancy> 6 months 4 Microbiological detection of CDI recurrence after at least an adequate standard antibiotic therapy with vancomycin> 125 mg / 4 times a day> 10 days or metronidazole 400 mg / 3 times a day 5. CDI-proof: - Diarrhea (> 3 in two consecutive days) - C. difficile toxin detection in stool
Exclusion criteria
Exclusion criteria: 1. Congenital or acquired immunodeficiency due to prolonged eg Chemotherapy / drugs (eg, long-term therapy with prednisolone 60 mg) 2. stage HIV AIDS with CD4 cell counts below 250 3. pregnancy / lactation 4. Unstable circulatory condition (catecholamine / Respiratory insufficiency)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation the willingness of patients to perform a stool therapy by means of questionnaires on day -2 before therapy resp. Days 1, 3, 7, 14, 30, 90 after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. analysis of the molecular and microbiological changes in stool from the receiver (day -2 before therapy; day 14, 30, 90 after treatment) 2. influence on the susceptibility to allergies or respiratory function (day -2 before therapy; 30 days after treatment) | — |
Countries
Germany
Contacts
Public ContactAlexander Link
Universitätsklinik für Gastroenterologie, Hepatologie und Infektiologie
Outcome results
None listed